Videos

Dr Victor Gonzalez discusses his presentation at ASRS, regarding 0.19mg fluocinolone acetonide implants in diabetic macular oedema (DMO) patients.

In his presentation at ASRS 2021, Dr Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular oedema in patients with retinal vein occlusion.

Dr W. Lloyd Clark discusses his presentation at ASRS 2021, "Impact of nonperfusion and leakage areas on diabetic macular oedema/vision-threatening complications in nonproliferative diabetic retinopathy (NPDR)."

Dr Leo Kim discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."

On October 14, we celebrate World Sight Day by pledging to receive annual eye exams, preventing or slowing vision loss, and showing love for our eyes.

Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

Dr Justis P. Ehlers discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021.

Prof Tunde Peto discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.

Dr Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.

Dr Grazia Pertile discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.

Dr Javier Zarranz-Ventura discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pretreated DMO patients, and what it means for future research.

Prof Carel B. Hoyng discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

Professor Quan Dong Nguyen speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.

The impact of the COVID-19 pandemic on the management of patients with retinal disorders and considerations for how new practices may be adopted into future practice.

Dr Mariya Moosajee comments on the next generation of gene therapy for inherited retinal disease and highlights various systems under investigation.

Considerations for treating retinal disorders with sustained-release drug delivery implants in an effort to address current treatment challenges in the field.

An overview of delivery systems under investigation for retinal disorders and implications for future use.

A discussion highlighting new agents under investigation for retinal disorders and implications for future use based on data revealed in more recent clinical trials.

Ophthalmologists highlight recent treatment advances in diabetic macular edema and wet age-related macular degeneration.

Types of delivery methods currently being explored to improve treatment for patients with retinal disorders.

Following a discussion regarding drug delivery challenges in retinal disease, a panel of global experts suggest what types of technological requirements and improvements they would like to see occur in the field.

Challenges associated with delivering therapies currently available to treat retinal disorders and methods being explored to improve drug delivery to patients.

Drawbacks and challenges associated with the administration of anti-VEGF injections currently available to treat retinal diseases.

Dr Mariya Moosajee highlights therapies approved as well as under study to improve treatment for patients with inherited retinal disease.

A discussion regarding the roles of various treatments available for diabetic macular edema and considerations for selecting and sequencing therapy.

An overview of the current treatment landscape for age-related macular degeneration and factors that impact treatment selection.